We are comparing Aduro BioTech Inc. (NASDAQ:ADRO) and Dova Pharmaceuticals Inc. (NASDAQ:DOVA) on their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation & Earnings

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Aduro BioTech Inc. and Dova Pharmaceuticals Inc.

Profitability

Table 2 represents Aduro BioTech Inc. (NASDAQ:ADRO) and Dova Pharmaceuticals Inc. (NASDAQ:DOVA)’s return on equity, return on assets and net margins.

Liquidity

The Current Ratio and Quick Ratio of Aduro BioTech Inc. are 9.1 and 9.1 respectively. Its competitor Dova Pharmaceuticals Inc.’s Current Ratio is 4.5 and its Quick Ratio is 4.3. Aduro BioTech Inc. can pay off short and long-term obligations better than Dova Pharmaceuticals Inc.

Analyst Recommendations

In next table is delivered Aduro BioTech Inc. and Dova Pharmaceuticals Inc.’s ratings and recommendations.

Aduro BioTech Inc.’s consensus target price is $7, while its potential upside is 260.82%.

Insider & Institutional Ownership

The shares of both Aduro BioTech Inc. and Dova Pharmaceuticals Inc. are owned by institutional investors at 44.1% and 41.7% respectively. Aduro BioTech Inc.’s share held by insiders are 1.1%. Competitively, insiders own roughly 49.4% of Dova Pharmaceuticals Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Aduro BioTech Inc. was less bullish than Dova Pharmaceuticals Inc.

Summary

On 6 of the 11 factors Dova Pharmaceuticals Inc. beats Aduro BioTech Inc.

Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases. It is developing CRS-207, which has completed Phase Ib clinical trials for the treatment of unresectable malignant pleural mesothelioma; that has completed Phase II clinical trials for the treatment of pancreatic cancer; and that is in Phase I/II clinical trials for the treatment of ovarian cancer. The company is also developing ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; ADU-741, which is in Phase I clinical trials for the treatment of prostate cancer; and a product candidate for the treatment of patients with cancers of the gastrointestinal tract. In addition, it is developing STING Pathway Activator product candidates that are synthetic small molecule immune modulators, which target and activate Stimulator of Interferon Genes receptor under collaboration with Novartis Pharmaceuticals Corporation; and product candidates that address other therapeutic areas, such as autoimmune and infectious diseases. Further, the companyÂ’s products pipeline comprises BION-1301, a B-select mAb novel therapy for multiple myeloma; and antibody product candidates, including APRIL for the treatment of multiple myeloma, as well as oncology therapies, such as CD27, PD-1, and CTLA-4. Aduro BioTech, Inc. has development and commercialization agreement with Genmab to evaluate five bispecific antibody product candidates targeting immune checkpoints; and collaboration agreement with Janssen Biotech, Inc. and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is headquartered in Berkeley, California.

Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia diseases. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver diseases. The company was founded in 2016 and is based in Durham, North Carolina.